CClinicalTrials.gg
Not yet recruitingNCT07849920Updated Sep 30, 2026

Walk Together Efficacy Trial

An interventional study of Walk Together and Hypertension education in Hypertension, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the Walk Together family-based intervention can improve hypertension self-management and blood pressure control in Black and African American primary care patients living with uncontrolled hypertension. The main questions it aims to answer are:

  • Do patients and family members who complete Walk Together take better care of their health?
  • Does Walk Together lower blood pressure? Researchers will compare the Walk Together intervention to a hypertension education intervention to see if Walk Together works to improve blood pressure.

Participants will:

  • Complete four study sessions over 7 to 10 weeks
  • Measure their blood pressure at home
  • Answer questions about their family and their health 6 times over 8 months
Read the detailed description

Hypertension is the most significant risk factor for racial disparities in mortality and life expectancy. African Americans, in particular, are at greater risk of developing hypertension earlier and experiencing worse hypertension-related outcomes. Hypertension is also a modifiable risk factor for cardiovascular disease, in part via self-management behavior which is critical for achieving hypertension control. Black and African American individuals often report difficulties with self-management adherence due in part to challenges in sustaining necessary lifestyle changes, and environmental barriers to engaging in self-care. African Americans also frequently report family emotional and behavioral support is critical for achieving self-management goals, while shared health behaviors, insufficient support, and family stress are often identified as barriers to self-management. Yet, family support has remained an untapped resource in hypertension self-management interventions. This study will test the efficacy of a new family-based hypertension self¬-management intervention which was designed and adapted with and for Black and African American primary care patients living with uncontrolled hypertension and their family support persons via prior community-based participatory research. The intervention -- Walk Together -- includes four dyadic (i.e., patient plus family support person) sessions over approximately eight weeks with the goal of optimizing family relationship quality including family support for hypertension self-management, plus improving hypertension knowledge, while addressing common barriers to hypertension management via referrals to standard of care resources, health information technology, and integration into patients' primary care clinics. Using a randomized controlled trial design, we will (1) identify the extent to which the Walk Together intervention increases hypertension self-management adherence and improves blood pressure control compared to a hypertension education control condition (HypEd); (2) examine family support (i.e., patient-family support person relationship quality, and family support for hypertension management behaviors) and hypertension knowledge as mechanisms of effect through which Walk Together leads to improvements in self-management adherence and blood pressure control outcomes; and, (3) evaluate the family-level positive health impacts of the Walk Together intervention on participating family support persons' hypertension knowledge and health behaviors.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Family support
  • Integrated health care systems
  • Healthy lifestyle
  • Hypertension
  • Community-based participatory research
  • Primary care
  • African American
  • Blood pressure
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Black or African American
  • Age 18 to 75
  • Diagnosis of essential hypertension
  • Two clinic-based blood pressure values ≥ 130/ ≥ 80 in 12 months prior
  • Available family support person to join the study who agrees to participate
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of hypertension is made exclusively during pregnancy
  • Documented cognitive impairment in patient's medical record
  • Presence of severe psychiatric condition (i.e., current psychotic disorder or suicidality)
  • Diagnosis of sustained atrial fibrillation
  • Past-year myocardial infarction
  • Diagnosis of chronic kidney disease (eGFR \<20)
  • Malignancy (other than non-melanoma skin cancer) in past 2 years
  • Prior organ transplant
  • Prior participation in earlier Walk Together studies
  • Participation in prior hypertension health education intervention
  • Family support person is under the age of 18 or over age of 25
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Walk Together

    Walk Together incudes four dyadic sessions, integrated into patients' primary care, to improve hypertension self-management adherence and blood pressure control via optimizing family relationship quality and increasing hypertension knowledge.

    Behavioral: Walk Together

  • Sham comparator
    Hypertension Education (HypEd)

    Hypertension education control condition includes four points of contact providing hypertension education and follow-up regarding hypertension self-management.

    Behavioral: Hypertension education

Interventions

  • BehavioralWalk Together

    Walk Together incudes four sessions delivered in patients' primary care clinics (in-person or via telehealth) over approximately eight weeks. Sessions are dyadic (i.e., all sessions include the patient participant plus the patient's self-identified family support person), last approximately 4 hours total (ranging from 30-90 minutes each), and are facilitated by a trained behavioral interventionist with expertise in couples and family therapy. The goals of the intervention are to (a) improve family relationship quality (i.e., dyadic relationship quality and family support for hypertension self-management) and (b) improve hypertension knowledge, in order to improve hypertension self-management adherence and improve blood pressure control. All participants are provided a blood pressure monitor for remote monitoring. Environmental barriers to self-management adherence are also addressed consistent with standard care.

  • BehavioralHypertension education

    HypEd includes four points of contact including one dyadic (i.e., patient participants plus patient-identified family support persons) baseline session (30 minutes) that includes education on use of study-provided blood pressure monitors and accurate blood pressure monitoring, hypertension basics, and hypertension self-management goal-setting. All dyads will receive a copy of NHLBI's "On the Move to Better Heart Health for African Americans" educational booklet. Patients will then receive a phone call to check-in regarding progress in their hypertension management goal and reviewing the educational booklet at 1-2 weeks, 3-4 weeks, and 7-10 weeks. All participants will receive a blood pressure monitor for remote monitoring.

05

What researchers measure

Primary outcomes

  1. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Baseline

  2. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Baseline

  7. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  8. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: Baseline

  12. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 1 month (readings completed within 7 days of session 3)

  13. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 2 months (readings completed within 7 days of session 4)

  14. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline, using 7-day averages)

  15. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline, using 7-day averages)

  16. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Baseline

  17. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 1

  18. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 2

  19. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. We will average all three measurements and the last two measurements at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used) and assess blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 7

Secondary outcomes

  1. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21; a cutoff score of greater than or equal to 13.5 indicates relationship distress.

    Time frame: Baseline

  2. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21; a cutoff score of greater than or equal to 13.5 indicates relationship distress.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21; a cutoff score of greater than or equal to 13.5 indicates relationship distress.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21; a cutoff score of greater than or equal to 13.5 indicates relationship distress.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21; a cutoff score of greater than or equal to 13.5 indicates relationship distress.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Baseline

  7. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  8. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV (FACES-IV) Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate greater support.

    Time frame: Baseline

  12. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate greater support.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  13. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate greater support.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  14. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate greater support.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  15. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5 where higher scores indicate greater support.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  16. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Baseline

  17. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  18. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  19. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  20. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

Other outcomes

  1. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Baseline

  2. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Baseline

  7. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  8. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the H-SCALE, a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol questionnaire which assesses current, past-year, and historical smoking behavior.

    Time frame: Baseline

  12. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol questionnaire which assesses current, past-year, and historical smoking behavior.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  13. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol questionnaire which assesses current, past-year, and historical smoking behavior.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  14. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol questionnaire which assesses current, past-year, and historical smoking behavior.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  15. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol questionnaire which assesses current, past-year, and historical smoking behavior.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  16. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol.

    Time frame: Baseline

  17. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  18. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  19. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  20. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  21. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Baseline

  22. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  23. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  24. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  25. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  26. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity.

    Time frame: Baseline

  27. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  28. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  29. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  30. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  31. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule.

    Time frame: Baseline

  32. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  33. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  34. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  35. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

06

Study locations

1 site
  • UT Southwestern Department of Family and Community Medicine
    Dallas, Texas 75390, United States
07

References and documents

Individual participant data

Plan to share: Yes — All direct respondent identifiers (e.g., names, EHR chart numbers) will be removed and maintained in a secure file for data linkage purposes, and will not be shared. Deidentification will be completed by the end of data processing, prior to the finalization of the public use data files. All other scientific data (survey data, EHR medical and blood pressure data) will be both preserved and shared, once deidentification is complete. A data dictionary which includes variable names, variable labels, question text as allowable, values, value labels, explanations of missing data, and scale-level descriptions and calculations, will also be shared.

Supporting information: Study protocol

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07849920
Lead sponsor
University of Texas Southwestern Medical Center
Collaborators
National Institute on Minority Health and Health Disparities (NIMHD)
Responsible party
Sarah Woods (Principal Investigator, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 30, 2026
Start date
Jan 18, 2027 (estimated)
Primary completion
Apr 18, 2031 (estimated)
Completion
Apr 18, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Study Coordinator
Contact
WalkTogether@UTSouthwestern.edu
214-645-9532
Sarah Woods, PhD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion